These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9820146)

  • 1. The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope.
    Buratti E; McLain L; Tisminetzky S; Cleveland SM; Dimmock NJ; Baralle FE
    J Gen Virol; 1998 Nov; 79 ( Pt 11)():2709-16. PubMed ID: 9820146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
    Cleveland SM; Buratti E; Jones TD; North P; Baralle F; McLain L; McInerney T; Durrani Z; Dimmock NJ
    Virology; 2000 Jan; 266(1):66-78. PubMed ID: 10612661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the gp41 C-terminal tail of human immunodeficiency virus type 1.
    Cleveland SM; Jones TD; Dimmock NJ
    J Gen Virol; 2000 May; 81(Pt 5):1251-60. PubMed ID: 10769067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41.
    Viveros M; Dickey C; Cotropia JP; Gevorkian G; Larralde C; Broliden K; Levi M; Burgess A; Cao C; Weiner DB; Agadjanyan MG; Ugen KE
    Virology; 2000 Apr; 270(1):135-45. PubMed ID: 10772986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different effects of a single amino acid substitution on three adjacent epitopes in the gp41 C-terminal tail of a neutralizing antibody escape mutant of human immunodeficiency virus type 1.
    McLain L; Brown JL; Cheung L; Reading SA; Parry C; Jones TD; Cleveland SM; Dimmock NJ
    Arch Virol; 2001; 146(1):157-66. PubMed ID: 11266210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.
    Eckhart L; Raffelsberger W; Ferko B; Klima A; Purtscher M; Katinger H; Rüker F
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2001-8. PubMed ID: 8810996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational display of two neutralizing epitopes of HIV-1 gp41 on the Flock House virus capsid protein.
    Buratti E; Tisminetzky SG; Scodeller ES; Baralle FE
    J Immunol Methods; 1996 Oct; 197(1-2):7-18. PubMed ID: 8890890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
    Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
    Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus.
    McLain L; Durrani Z; Wisniewski LA; Porta C; Lomonossoff GP; Dimmock NJ
    Vaccine; 1996 Jun; 14(8):799-810. PubMed ID: 8817828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus.
    McLain L; Porta C; Lomonossoff GP; Durrani Z; Dimmock NJ
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):327-34. PubMed ID: 7786579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Construction of peptide mimetics of an epitope of the human immunodeficiency virus (HIV-1) gp41 protein, recognized by virus-neutralizing antibodies 2F5].
    Tumanova OIu; Kuvshinov VN; Azaev MSh; Masharskiĭ AE; Klimov NA; Kozlov AP; Il'ichev AA; Sandakhchiev LS
    Mol Biol (Mosk); 2001; 35(1):146-51. PubMed ID: 11234374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion.
    Cleveland SM; McLain L; Cheung L; Jones TD; Hollier M; Dimmock NJ
    J Gen Virol; 2003 Mar; 84(Pt 3):591-602. PubMed ID: 12604810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope.
    Li J; Chen X; Jiang S; Chen YH
    Biochem Biophys Res Commun; 2008 Nov; 376(1):60-4. PubMed ID: 18762167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
    Neurath AR; Strick N; Lee ES
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
    Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
    Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41.
    Rey-Cuillé MA; Svab J; Benferhat R; Krust B; Briand JP; Muller S; Hovanessian AG
    J Pharm Pharmacol; 2006 Jun; 58(6):759-67. PubMed ID: 16734977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.
    Bryson S; Julien JP; Isenman DE; Kunert R; Katinger H; Pai EF
    J Mol Biol; 2008 Oct; 382(4):910-9. PubMed ID: 18692506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Composition of HIV-1 B-epitopes and heterologous T-cell epitopes. I. Maintenance of antigenic properties of HIV-1 B-epitopes].
    Isaguliants MG; Koshida R; Ruden U; Varen B
    Biokhimiia; 1996 Jul; 61(7):1221-9. PubMed ID: 9035735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion-active intermediate state.
    Sadler K; Zhang Y; Xu J; Yu Q; Tam JP
    Biopolymers; 2008; 90(3):320-9. PubMed ID: 18338371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5.
    Kusov YY; Zamjatina NA; Poleschuk VF; Michailov MI; Morace G; Eberle J; Gauss-Müller V
    Antiviral Res; 2007 Feb; 73(2):101-11. PubMed ID: 17014915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.